Quick Answer
China SXT Pharmaceuticals, Inc. reported Net Income of -$3.30 million for fiscal year 2025.
China SXT Pharmaceuticals, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$3.30M | -6.6% |
| 2024 | -$3.10M | +47.8% |
| 2023 | -$5.93M | -3.5% |
| 2022 | -$5.74M | -108.7% |
| 2021 | -$2.75M | +73.3% |
| 2020 | -$10.29M | -768.4% |
| 2019 | $1.54M | +29.6% |
| 2018 | $1.19M | +0.2% |
| 2017 | $1.19M | — |
- China SXT Pharmaceuticals, Inc. showed a decrease of -6.6% in Net Income compared to the prior fiscal year.
- Over the 2017–2025 period, China SXT Pharmaceuticals, Inc.’s net income has declined by 378.8% (from $1.19 million to -$3.30 million).
- The most recent figure is from China SXT Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 20-F), filed with the SEC on July 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: